Research output per year
Research output per year
Personal profile
Research Biography
Professor Miners was a Postdoctoral Research Scientist at Oxford University before taking up a position as Toxicologist in the Department of Biochemistry and Chemical Pathology of Flinders Medical Centre in 1977. He joined the Department of Clinical Pharmacology in 1978. Until 2002 Prof Miners held the positions of Chief Pharmacologist and Professor in Clinical Pharmacology. From 2003 to 2013, he was Professor and Head of the Department of Clinical Pharmacology. He currently holds a part-time research only position as Professor of Pharmacology and Therapeutics.
Research Interests
Drug and chemical metabolism in humans, particularly sources of variability in drug elimination and its pharmacokinetic and therapeutic consequences. Current interests include:
- Structure-function relationships and genetic polymorphisms of human UDP-glucuronosyltransferases and cytochromes P450
- In vitro (in vitro-in vivo extrapolation) and computational models for the prediction of drug and chemical metabolism parameters in vivo
- Drug-drug interactions
- Metabolomics (including biomarkers of drug response)
- Therapeutic drug monitoring
Completed Supervisions
Principal Supervisions:
- Pharmacology and Therapeutics (20)
Supervision
- Registered
Research Areas
- Medical biosciences
Fingerprint
Dive into the research topics where John Miners is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance
Miners, J. O., Polasek, T. M., Hulin, J. A., Rowland, A. & Meech, R., Aug 2023, In: Pharmacology and Therapeutics. 248, 58 p., 108459.Research output: Contribution to journal › Review article › peer-review
11 Citations (Scopus) -
The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation
Nair, P. C., Burns, K., Chau, N., McKinnon, R. A. & Miners, J. O., Dec 2023, In: Journal of Biological Chemistry. 299, 12, 17 p., 105368.Research output: Contribution to journal › Article › peer-review
Open AccessFile37 Downloads (Pure) -
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer
Hopkins, A. M., Sorich, M. J., McLachlan, A. J., Karapetis, C. S., Miners, J. O., van Dyk, M. & Rowland, A., 14 Feb 2023, (E-pub ahead of print) In: JCO Precision Oncology. 7, 10 p., e2200538.Research output: Contribution to journal › Article › peer-review
-
Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs
Nair, P. C., Miners, J. O., McKinnon, R. A., Langmead, C. J., Gregory, K. J., Copolov, D., Chan, S. K. W. & Bastiampillai, T., Jan 2022, In: MOLECULAR PSYCHIATRY. 27, 1, p. 88-94 7 p.Research output: Contribution to journal › Review article › peer-review
20 Citations (Scopus) -
Inhibitory effects of non-steroidal anti-inflammatory drugs on human liver microsomal morphine glucuronidation: Implications for drug-drug interaction liability
Uchaipichat, V., Rowland, A. & Miners, J. O., Feb 2022, In: Drug Metabolism and Pharmacokinetics. 42, 9 p., 100442.Research output: Contribution to journal › Article › peer-review
5 Citations (Scopus)
Activities
- 6 Oral presentation
-
Kinetic characterisation of S-naproxen glucuronidation by human kidney cortical microsomes and recombinant UGT 1A9 and UGT2B7
Kathie Knights (Speaker), Voula Gaganis (Speaker), Kushari Burns (Speaker), David Elliot (Speaker) & John Miners (Speaker)
1 Jan 2004Activity: Talk or presentation types › Oral presentation
-
NSAID-arachidonic acid interactions are intimately linked to the nephrotoxic potential of NAIDs during renal ischaemia
Voula Gaganis (Speaker), John Miners (Speaker) & Kathie Knights (Speaker)
30 Nov 2003Activity: Talk or presentation types › Oral presentation
-
Unsaturated fatty acids: potent inhibitors of renal UDP-glucuronosyltransferases (UGT)
Voula Gaganis (Speaker), B Sallustio (Speaker), John Miners (Speaker) & Kathie Knights (Speaker)
19 Aug 2003Activity: Talk or presentation types › Oral presentation
-
Fatty acids are potent inhibitors of 4-methylumbelliferone glucuronidation by human renal and recombinant UDP-glucuronosyltransferases
Voula Gaganis (Speaker), John Miners (Speaker), Kathie Knights (Speaker) & B Sallustio (Speaker)
7 Jul 2002Activity: Talk or presentation types › Oral presentation
-
The effect of fatty acids on the glucuronidation of 4-methyl-um-belliferone (4-MU) by human kidney cortical microsomes
Kathie Knights (Speaker), Voula Gaganis (Speaker), John Miners (Speaker) & B Sallustio (Speaker)
7 Oct 2001 → 11 Oct 2001Activity: Talk or presentation types › Oral presentation